Baseline characteristics of the patients
| Characteristic . | Dasatinib (n = 101) . | High-dose imatinib (n = 49) . |
|---|---|---|
| Age, y | ||
| Median | 51 | 51 |
| Range | 24-85 | 24-80 |
| Male, no. (%) | 53 (52) | 22 (45) |
| Disease history, duration in months, median (range) | 64 (6-166) | 52 (14-133) |
| History of imatinib therapy | ||
| Max imatinib dose >400 mg/day; no. (%) | 65 (64) | 35 (71) |
| Duration of prior imatinib therapy, no. (%) | ||
| Less than 1 year | 12 (12) | 5 (10) |
| 1-3 years | 44 (44) | 29 (59) |
| 3 years or more | 45 (45) | 15 (31) |
| Prior response to imatinib, no. (%) | ||
| CHR | 93 (92) | 47 (96) |
| CCyR | 15 (15) | 4 (8) |
| PCyR | 13 (13) | 10 (20) |
| Reason for imatinib resistance,* no. (%) | ||
| Loss of MCyR | 21 (21) | 14 (29) |
| Loss of CHR | 24 (24) | 15 (31) |
| Increasing white blood cell count | 4 (4) | 2 (4) |
| No CHR after 3 months | 3 (3) | 2 (4) |
| No CyR after 6 months | 39 (39) | 16 (33) |
| No MCyR after 12 months | 39 (39) | 24 (49) |
| Treatment history, no. (%) | ||
| Hydroxyurea/anagrelide | 97 (96) | 46 (94) |
| Interferon-α | 74 (73) | 33 (67) |
| Chemotherapy | 39 (39) | 18 (37) |
| Bone marrow transplant | 7 (7) | 2 (4) |
| Hematologic analysis | ||
| WBC count, × 109/L | ||
| Median | 7.5 | 7.4 |
| Range | 2-153 | 2-133 |
| WBC count, 20 × 109/L or more, % | 11 | 14 |
| Platelet count, × 109/L | ||
| Median | 256 | 248 |
| Range | 55-1903 | 80-2318 |
| Mutation status, BCR-ABL mutation; n/N (%) | 41/92 (45) | 11/46 (24) |
| Response status, no. (%) | ||
| Patients in CHR at entry | 51 (50) | 27 (55) |
| Patients in MCyR at entry | 6 (6) | 0 |
| Characteristic . | Dasatinib (n = 101) . | High-dose imatinib (n = 49) . |
|---|---|---|
| Age, y | ||
| Median | 51 | 51 |
| Range | 24-85 | 24-80 |
| Male, no. (%) | 53 (52) | 22 (45) |
| Disease history, duration in months, median (range) | 64 (6-166) | 52 (14-133) |
| History of imatinib therapy | ||
| Max imatinib dose >400 mg/day; no. (%) | 65 (64) | 35 (71) |
| Duration of prior imatinib therapy, no. (%) | ||
| Less than 1 year | 12 (12) | 5 (10) |
| 1-3 years | 44 (44) | 29 (59) |
| 3 years or more | 45 (45) | 15 (31) |
| Prior response to imatinib, no. (%) | ||
| CHR | 93 (92) | 47 (96) |
| CCyR | 15 (15) | 4 (8) |
| PCyR | 13 (13) | 10 (20) |
| Reason for imatinib resistance,* no. (%) | ||
| Loss of MCyR | 21 (21) | 14 (29) |
| Loss of CHR | 24 (24) | 15 (31) |
| Increasing white blood cell count | 4 (4) | 2 (4) |
| No CHR after 3 months | 3 (3) | 2 (4) |
| No CyR after 6 months | 39 (39) | 16 (33) |
| No MCyR after 12 months | 39 (39) | 24 (49) |
| Treatment history, no. (%) | ||
| Hydroxyurea/anagrelide | 97 (96) | 46 (94) |
| Interferon-α | 74 (73) | 33 (67) |
| Chemotherapy | 39 (39) | 18 (37) |
| Bone marrow transplant | 7 (7) | 2 (4) |
| Hematologic analysis | ||
| WBC count, × 109/L | ||
| Median | 7.5 | 7.4 |
| Range | 2-153 | 2-133 |
| WBC count, 20 × 109/L or more, % | 11 | 14 |
| Platelet count, × 109/L | ||
| Median | 256 | 248 |
| Range | 55-1903 | 80-2318 |
| Mutation status, BCR-ABL mutation; n/N (%) | 41/92 (45) | 11/46 (24) |
| Response status, no. (%) | ||
| Patients in CHR at entry | 51 (50) | 27 (55) |
| Patients in MCyR at entry | 6 (6) | 0 |
CCyR indicates complete cytogenetic response; CHR, complete hematologic response; CyR, cytogenetic response; MCyR, major cytogenetic response; PCyR, partial cytogenetic response; WBC, white blood cells; n/N, datum number/number of patients treated.
Patients may have more than one reason for imatinib resistance.